New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
J Frau, G Coghe, L Lorefice, G Fenu… - … disease and treatment, 2018 - Taylor & Francis
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
[HTML][HTML] New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
J Frau, G Coghe, L Lorefice, G Fenu… - … Disease and Treatment, 2018 - ncbi.nlm.nih.gov
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
J Frau, G Coghe, L Lorefice, G Fenu… - NEUROPSYCHIATRIC …, 2018 - iris.unica.it
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
J Frau, G Coghe, L Lorefice… - Neuropsychiatric …, 2018 - pubmed.ncbi.nlm.nih.gov
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab.
J Frau, G Coghe, L Lorefice, G Fenu… - … Disease and Treatment, 2018 - europepmc.org
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab.
J Frau, G Coghe, L Lorefice, G Fenu… - … Disease & Treatment, 2018 - search.ebscohost.com
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
J Frau, G Coghe, L Lorefice, G Fenu… - … Disease and Treatment, 2018 - go.gale.com
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
J Frau, G Coghe, L Lorefice, G Fenu… - Neuropsychiatric …, 2018 - search.proquest.com
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
[PDF][PDF] New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
J Frau - Neuropsychiatric Disease and Treatment, 2018 - scienceopen.com
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
J Frau, G Coghe, L Lorefice, G Fenu… - … Disease and Treatment, 2018 - dovepress.com
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …
nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of …